Novo Nordisk A/S Sponsored ADR (NVO)
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q1 Results?
Novo Nordisk's Q1 performance hinges on Ozempic and Wegovy sales, but rising competition, pricing pressure and muted 2026 guidance may temper growth momentum.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
The latest trading day saw Novo Nordisk (NVO) settling at $40.52, representing a -1% change from its previous close.
NVO Inks Deal With OpenAI for Speedy Drug Discovery Globally, Stock Up
Novo Nordisk stock up as it teams up with OpenAI to deploy AI across drug discovery and operations, aiming to speed therapies, boost efficiency and counter rising competition.
Novo Nordisk weight-loss drug shows liver benefits in mouse study
GLP-1 drugs have direct beneficial effects on the liver, independent of their benefits for obesity, researchers studying the medicines in mice with fatty liver disease have found.
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Novo Nordisk faces rising pressure as LLY launches Foundayo, a rival obesity pill, challenging Wegovy despite data suggesting NVO's edge in efficacy.
Is Ozempic maker stock a buy after OpenAI partnership?
Novo Nordisk (NYSE: NVO), the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with OpenAI.
Novo Nordisk and OpenAI Partner to Speed Drug Discovery
The strategic partnership will integrate OpenAI's advanced AI capabilities throughout the drugmaker's operations, helping employees to analyze data and identify new drug candidates.
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
Danish drugmaker Novo Nordisk , which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on Tuesday it is partnering with OpenAI to deploy artificial intelligence across its business, from drug discovery to manufacturing and commercial operations.
NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?
Novo Nordisk plunges 36% in three months as a weak 2026 outlook, rising competition and pricing pressure cloud near-term growth despite long-term pipeline promise.
Novo Nordisk: Don't Stop Purchasing The Dip
Novo Nordisk remains a compelling investment despite share price weakness, driven by robust innovation and a resilient, diversified drug pipeline. NVO delivered 10% sales growth, $5B FCF, and a 4.8% dividend yield in 2025, comfortably funding both dividends and buybacks. GLP-1 competition is intensifying, but market expansion and strong international growth offset U.S. market share erosion, supporting continued revenue strength.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo Nordisk (NVO) Increases Yet Falls Behind Market: What Investors Need to Know
In the most recent trading session, Novo Nordisk (NVO) closed at $37.61, indicating a +1.9% shift from the previous trading day.
